Phathom Pharmaceuticals Inc. PHAT
$10.54
▲ +0.97% 24H
About
Phathom Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases related to acid. Its flagship product, VOQUEZNA (vonoprazan), a potassium-competitive acid blocker, is approved for adults with erosive gastroesophageal reflux disease (GE…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees371
TickerPHAT
Statistics
Market Cap$837.7M
Revenue (TTM)$175.1M
Net Income-$221.2M
Net Margin-126.3%
EPS$-3.03
P/E-3.47
P/S4.00
P/B-2.56
EV/EBITDA-11.97
ROE50.5%
Dividend Yield—
Price$10.54
Data: Twelve Data · Revenue = mcap / P/S